Advanced

Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin

Schmidt, M ; Sorbe, B ; Högberg, T LU ; Himmelmann, A ; Räisänen, I ; Stockmeyer, M and de Bruijn, K M (1993) In Annals of oncology : official journal of the European Society for Medical Oncology 4(Suppl 3). p.31-34
Abstract

A multicentre study was performed at four oncology centres in Sweden, in 160 chemotherapy-naive women, primarily with ovarian or endometrial carcinomas. Abdominal surgery preceded chemotherapy in 146 (91%) women, and another 39 (24%) women had a history of radiotherapy. The chemotherapy regimens contained cisplatin (50-100 mg/m2), in combination with a variety of other agents. In Course 1, all patients received tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6) and 84% of patients achieved total or partial control of vomiting; 95% of patients achieved total or partial control of nausea during the first 24 hours. Vomiting was least successfully controlled on Day 2 (73% total or partial control) and Days 2-4 for the control of nausea (81,... (More)

A multicentre study was performed at four oncology centres in Sweden, in 160 chemotherapy-naive women, primarily with ovarian or endometrial carcinomas. Abdominal surgery preceded chemotherapy in 146 (91%) women, and another 39 (24%) women had a history of radiotherapy. The chemotherapy regimens contained cisplatin (50-100 mg/m2), in combination with a variety of other agents. In Course 1, all patients received tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6) and 84% of patients achieved total or partial control of vomiting; 95% of patients achieved total or partial control of nausea during the first 24 hours. Vomiting was least successfully controlled on Day 2 (73% total or partial control) and Days 2-4 for the control of nausea (81, 83, 88% total or partial control, respectively). Patients with partial response in Course 1 (39% of patients) were randomized to addition of dexamethasone or placebo in Course 2. In Course 2, tropisetron plus dexamethasone (Group B2) prevented acute vomiting in 75% of patients, compared with 40% of patients receiving tropisetron plus placebo (Group B1). Over the entire 6 days, there was no vomiting at all in 54% and 20% of B2 and B1 patients, respectively. In Course 2, acute nausea was prevented in 75% of patients (receiving B1) and in 37% of patients (receiving B2). For nausea, over the complete 6 days, the figures were 64% and 3% (p < 0.001). This indicated that patients with incomplete control of emesis in Course 1 benefited from the addition of dexamethasone, provided that it was added for each of the 6 days studied.(ABSTRACT TRUNCATED AT 250 WORDS)

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Aged, Aged, 80 and over, Antiemetics/administration & dosage, Cisplatin/adverse effects, Dexamethasone/administration & dosage, Drug Therapy, Combination, Female, Humans, Indoles/administration & dosage, Middle Aged, Nausea/chemically induced, Serotonin Antagonists/administration & dosage, Tropisetron, Vomiting/chemically induced
in
Annals of oncology : official journal of the European Society for Medical Oncology
volume
4
issue
Suppl 3
pages
31 - 34
publisher
Oxford University Press
external identifiers
  • pmid:8363997
ISSN
0923-7534
DOI
10.1093/annonc/4.suppl_3.s31
language
English
LU publication?
no
id
34c63eca-fa0a-46fa-9411-272f45cbb347
date added to LUP
2019-09-20 08:15:05
date last changed
2020-12-19 04:03:09
@article{34c63eca-fa0a-46fa-9411-272f45cbb347,
  abstract     = {<p>A multicentre study was performed at four oncology centres in Sweden, in 160 chemotherapy-naive women, primarily with ovarian or endometrial carcinomas. Abdominal surgery preceded chemotherapy in 146 (91%) women, and another 39 (24%) women had a history of radiotherapy. The chemotherapy regimens contained cisplatin (50-100 mg/m2), in combination with a variety of other agents. In Course 1, all patients received tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6) and 84% of patients achieved total or partial control of vomiting; 95% of patients achieved total or partial control of nausea during the first 24 hours. Vomiting was least successfully controlled on Day 2 (73% total or partial control) and Days 2-4 for the control of nausea (81, 83, 88% total or partial control, respectively). Patients with partial response in Course 1 (39% of patients) were randomized to addition of dexamethasone or placebo in Course 2. In Course 2, tropisetron plus dexamethasone (Group B2) prevented acute vomiting in 75% of patients, compared with 40% of patients receiving tropisetron plus placebo (Group B1). Over the entire 6 days, there was no vomiting at all in 54% and 20% of B2 and B1 patients, respectively. In Course 2, acute nausea was prevented in 75% of patients (receiving B1) and in 37% of patients (receiving B2). For nausea, over the complete 6 days, the figures were 64% and 3% (p &lt; 0.001). This indicated that patients with incomplete control of emesis in Course 1 benefited from the addition of dexamethasone, provided that it was added for each of the 6 days studied.(ABSTRACT TRUNCATED AT 250 WORDS)</p>},
  author       = {Schmidt, M and Sorbe, B and Högberg, T and Himmelmann, A and Räisänen, I and Stockmeyer, M and de Bruijn, K M},
  issn         = {0923-7534},
  language     = {eng},
  number       = {Suppl 3},
  pages        = {31--34},
  publisher    = {Oxford University Press},
  series       = {Annals of oncology : official journal of the European Society for Medical Oncology},
  title        = {Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin},
  url          = {http://dx.doi.org/10.1093/annonc/4.suppl_3.s31},
  doi          = {10.1093/annonc/4.suppl_3.s31},
  volume       = {4},
  year         = {1993},
}